Search results
Results from the WOW.Com Content Network
Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. [1] [2] It is used together with a diabetic diet and exercise. [1] [2] It is not indicated for use by itself in type 1 diabetes. [1] [2] It is taken by mouth.
The study included over 54,000 U.S. adolescents and found a 33% reduction in the risk of suicidal thoughts and attempts among those using the drugs compared to those who did not. [33] Additionally, while adolescents taking GLP-1 drugs experienced more gastrointestinal symptoms, they had a lower risk of acute pancreatitis compared to the control ...
A study confirmed that side effects like pancreatitis and kidney damage are possible while taking GLP-1s like Ozempic. Here's what a doctor wants you to know. ... “I do believe the benefits ...
A European Medicines Agency review concluded that there is a potential increased risk of lower limb amputation (mostly affecting the toes) in people taking canagliflozin, dapagliflozin and empagliflozin. [17] In August 2018, the FDA issued a warning of an increased risk of Fournier gangrene in patients using SGLT2 inhibitors. [18]
According to over two million smart-bed customers from Sleep Number, more people are reaping the benefits of an earlier night’s sleep. The average bedtime for younger adults crept down to 10:06 ...
Another small study on people without diabetes who were overweight or had obesity found that those taking metformin lost between 5.6 and 6.5 percent of their body weight. In contrast, the control ...
Alpha-glucosidase inhibitors are used to establish greater glycemic control over hyperglycemia in diabetes mellitus type 2, particularly with regard to postprandial hyperglycemia. The intake of a single dose before a meal containing complex carbohydrates clearly suppresses the glucose spike and may decrease the postprandial hyperglycemia ...
The Women's Health Initiative (WHI) was a series of clinical studies initiated by the U.S. National Institutes of Health (NIH) in 1991, to address major health issues causing morbidity and mortality in postmenopausal women. It consisted of three clinical trials (CT) and an observational study (OS).